الفهرس 
Circulating microRNAs 210 and 23b as potential novel biomarkers for bladder cancer
AbstractOnly 14 pages are availabe for public view
 |  | from | 194 |  |  |
| | | from | 194 | | |
Abstract
Background: Bladder carcinoma (BC) is one of the most common and lethal malignant tumors worldwide. MicroRNAs are involved in the epigenetic mechanisms implicated in BC molecular pathogenesis. Measuring the levels of the circulating miRNAs to be used as biomarkers for malignancies has recently been investigated in the hope of identifying unique miRNA signatures in human tumors. Two microRNAs have been selected in this study; miRNA 210 and miRNA 23b. Aim of the study: To identify miRNA 210 and miRNA 23b relative expression levels in the sera of BC patients. Methods: This study was conducted on 93 Egyptian adults who were divided into three groups: group I: included 31 newly diagnosed patients with bladder cancer. group II: included the same 31 patients of group I after 6 months from their medical and/or surgical treatment, group III: included 31 apparently healthy subjects as a control group. They were subjected to routine laboratory investigations and gene expression analysis for miRNA 210 and miRNA 23b using quantitative SYBR Green reverse-transcription Real-Time polymerase chain reaction. Results: It was found that median values of fold change (FC) of miRNA 210 were significantly higher in the sera of BC patients than in the control group (p =0.012). While there was no statistically significant difference in the median values of fold change (FC) of miRNA 23b between BC patients and the healthy control group p= 0.188